Jam tomorrow from Biotech
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.d by the end of this year. As a replacement for chemotherapy, this could have implications for treating one of the scourges of the modern world. Another compound which could show results this year is lexipafant, a treatment for acute pancreatitis.
But all these drugs merely hold out the prospect of jam tomorrow. Until there is more to go on, there is little to justify the current market capitalisation of pounds 240m, apart from a rapidly dwindling cash pile which was worth pounds 42m at the year end. Highly speculative.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments